Experience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia

Simple item page
dc.contributor.authorVan Riet F.A.D.
dc.contributor.authorWessels G.
dc.contributor.authorHesseling P.B.
dc.date.accessioned2011-05-15T16:16:16Z
dc.date.available2011-05-15T16:16:16Z
dc.date.issued1999
dc.description.abstractObjective: To evaluate the efficacy of high dose dexamethasone (HDD) as treatment for symptomatic chronic immune thrombocytopaenia (ITP). Design: A non-randomised intervention study with final evaluation one year after treatment, comparing findings before and after intervention. Setting: Tygerberg University Hospital, South Africa. Participants: A consecutive sample of six children with chronic (duration more than six months) ITP. The diagnosis of ITP was based on a platelet count of < 100 × 109/1 together with appropriate clinical, laboratory and bone marrow findings. Interventions: All children treated with dexamethasone 0.5 mg/kg/day intravenously for four days every 28 days for a total of six cycles. Main outcome measures: A rise in platelet count maintained for a least one year associated with the disappearance of symptoms due to thrombocytopaenia. Results: Treatment was easy to administer and well tolerated with transient side effects in only two children. Three patients had a rise in platelet count of > 50 × 109/1 during treatment and three had platelet counts of > 30 × 109/1 after completion of therapy but only one at one month and one at six months after completion of the six courses respectively. None of the patients showed a sustained rise in platelet count during and after HDD treatment Conclusion: HDD did not cause a significant sustained rise in the platelet count in children with chronic symptomatic ITP. If high dose prednisone and IVIG fail, a splenectomy should be considered in children over five years of age.
dc.description.versionArticle
dc.identifier.citationEast African Medical Journal
dc.identifier.citation76
dc.identifier.citation10
dc.identifier.issn0012835X
dc.identifier.urihttp://hdl.handle.net/10019.1/13706
dc.subjectantiinflammatory agent
dc.subjectdexamethasone
dc.subjectimmunoglobulin
dc.subjectarticle
dc.subjectblood
dc.subjectbone marrow examination
dc.subjectchild
dc.subjectchronic disease
dc.subjectdrug effect
dc.subjectfemale
dc.subjecthuman
dc.subjectidiopathic thrombocytopenic purpura
dc.subjectinfant
dc.subjectintravenous drug administration
dc.subjectmale
dc.subjectpatient selection
dc.subjectpreschool child
dc.subjectsplenectomy
dc.subjectthrombocyte count
dc.subjecttreatment outcome
dc.subjectAnti-Inflammatory Agents
dc.subjectBone Marrow Examination
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectChronic Disease
dc.subjectDexamethasone
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunoglobulins, Intravenous
dc.subjectInfant
dc.subjectInfusions, Intravenous
dc.subjectMale
dc.subjectPatient Selection
dc.subjectPlatelet Count
dc.subjectPurpura, Thrombocytopenic, Idiopathic
dc.subjectSplenectomy
dc.subjectTreatment Outcome
dc.titleExperience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications